Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Endometrial Carcinosarcoma: early-phase trial registry

A small indexed set (2 trials) with no open enrollment listed right now.

Corpus placement: #7,188 of 28,707 conditions by registered trial count.

2 US clinical trials · none currently recruiting · #7,188 of 28,707 conditions by registered trial count

Endometrial Carcinosarcoma: 2 US clinical trials tracked, none currently recruiting.

Endometrial Carcinosarcoma is the subject of 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 2 of these trials.

Enrollment posture brief

Registry condition endometrial-carcinosarcoma

OPEN 0 | RECR 0% | LATE 0 | EARLY 2 | RANK #7188 | SPON 2

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Endometrial Carcinosarco (th…0%
Open-enrollment share among volume-matched conditions near Endometrial Carcinosarcoma

Endometrial Carcinosarcoma has no open enrollment in this registry pull (2 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Endometrial Carcinosarcoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Endometrial Carcinosarcoma is recruiting below its size-band peers.

    0 of 2 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 22

Phase Distribution

PhaseTrial count
Phase 2 2

Named interventions

Most-linked intervention names on Endometrial Carcinosarcoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

BMS- 986205 Drug
1 trials
Nivolumab Drug
1 trials
Olaparib Drug
1 trials
Pembrolizumab Drug
1 trials

US sites by state

Facility locations filed on Endometrial Carcinosarcoma trials. A trial with sites in several states counts in each.

New York 2 trials
New Jersey 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Endometrial Carcinosarcoma page

2 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Endometrial Carcinosarcoma condition card totals 2 registered trials; most-linked intervention BMS- 986205; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.